Microvascular and macrovascular complications associated with diabetes in children and adolescents
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The long-term vascular complications of diabetes include retinopathy, nephropathy, neuropathy and macrovascular disease. The outcomes are: visual impairment and blindness due to diabetic retinopathy renal failure and hypertension due to diabetic nephropathy pain, paraesthesiae, muscle weakness and autonomic dysfunction due to diabetic neuropathy cardiac disease, peripheral vascular disease and stroke due to macrovascular disease Clinically evident diabetes-related vascular complications should be rare in childhood and adolescence. However, early functional and structural abnormalities may be present a few years after the onset of the disease. Childhood and adolescence is a period during which intensive education and treatment may prevent or delay the onset and progression of complications. 1 A. There has been a declining incidence of complications reported in many areas with specialised clinics 2-4. This has occurred over a period of time during which there have been major changes in diabetes management, identification of putative risk factors, and the advent of regular screening for complications. There is no evidence that this is a world-wide occurrence: in areas where health care is not optimal, a greater risk of complications will remains. The Diabetes Control and Complications Trial (DCCT) was a multicentre, randomised controlled clinical trial involving 1441 patients with type 1 diabetes conducted in North America from 1983–1993 5. At recruitment 195 were pubertal adolescents (aged 13–17 years): there were no children 1. After completion of the DCCT (a median in the adolescent group of 7.4 years) and hence the end of randomisation to the two treatment groups (intensive and conventional treatment), the Epidemiology of Diabetes Interventions and Complications (EDIC) study continued to follow patients 6. After 4 years there was no significant difference in HbA1c between the former intensive and conventional treatment groups. The DCCT provided unequivocal evidence that intensive diabetes treatment and improved glycemic control conferred a significant risk reduction for microvascular complications compared with conventional treatment 5A. The EDIC study has shown that this positive effect continued after randomisation, i.e. that there was a memory effect of the improved glycaemic control. In addition it showed a positive effect of intensive therapy for reduction in macrovascular disease 7A. In the adolescent cohort, intensive treatment compared with conventional treatment, reduced the risk and progression of background retinopathy by 53%, clinical neuropathy by 60% and microalbuminuria by 54%. The difference in HbA1c was 8.1 vs 9.8%. The benefits of intensive therapy persisted in the former adolescent cohort during the EDIC study: the previously intensively managed group had 74% less retinopathy, 48% less microalbuminuria and 85% less albuminuria 6. Compared with conventional treatment, intensive treatment in the total age group reduced the risk of clinical neuropathy by 60%. Cardiovascular events were reduced by 50% in the previously intensively treated group compared to the control group during a mean 17 years follow-up 7. The DCCT confirmed that improved glycemic control may initially worsen diabetic retinopathy. However within 1.5 to 3 years, the advantage of intensive treatment is evident 8-10. In the DCCT, the long-term benefits of intensive insulin treatment greatly outweighed the risk of early retinal deterioration. Ophthalmological monitoring is recommended before initiation of intensive treatment and at 3 month intervals for 6–12 months thereafter for patients with long-standing poor glycaemic control, particularly if retinopathy severity is at or past the moderate nonproliferative stage at the time of intensification E. Longer duration of diabetes, older age and puberty are risk factors for complications 11. The prepubertal years of diabetes duration have a significant lesser impact especially further from the onset of gonadarche 12B. For the same diabetes duration, age and puberty increase the risk for retinopathy and elevated AER 13B. Smoking is associated with an increased risk of developing persistent microalbuminuria or macroalbuminuria 4, 14. The evidence for the effect of smoking on retinopathy is less clear. Type 1 diabetes and smoking interact to produce excess cardiovascular morbidity and mortality 15B. Hypertension has a greater impact on cardiovascular disease in diabetic patients than in non-diabetic individuals 16. Blood pressure control (< 130/80 mmHg in adults) is effective in decreasing cardiovascular morbidity and mortality in diabetes 17A. Dyslipoproteinaemia is associated with microalbuminuria and retinopathy development in the DCCT/EDIC 18, 19. This included higher total and LDL cholesterol and higher triglyceride levels for microalbuminuria, as well as larger LDL particle size and apoprotein B in men B. Family history of complications increases the risk for nephropathy 20 an
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063 · cited 1×
“Hypertension has a greater impact on cardiovascular disease in diabetic patients than in non-diabetic individuals (16).”
BackgroundMajor congenital malformations after first-trimester exposure to ACE inhibitors
Cooper, W. O., Hernandez-Diaz, S., Arbogast, P. G., Dudley, J. A., Dyer, S., Gideon, P. S., Hall, K., & Ray, W. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055202 · Cited by 1,192
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875
Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes
Laing, S. P., Swerdlow, A. J., Slater, S. D., Burden, A. C., Morris, A., Waugh, N. R., Gatling, W., Bingley, P. J., & Patterson, C. C. (2003) · Diabetologia · doi:10.1007/s00125-003-1116-6 · Cited by 724
Management of dyslipidemia in children and adolescents with diabetes
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.7.2194 · Cited by 438
Cited by
Flynn, J. T., Kaelber, D. C., Baker-Smith, C. M., Blowey, D., Carroll, A. E., Daniels, S. R., de Ferranti, S. D., Dionne, J. M., Falkner, B., Flinn, S. K., et al. (2017) · Pediatrics · doi:10.1542/peds.2017-1904 · Cited by 3,651
Virk, S. A., Donaghue, K. C., Cho, Y. H., Benitez-Aguirre, P., Hing, S., Pryke, A., Chan, A., & Craig, M. E. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3604 · Cited by 109
Self-citation
Metadata
- Authors
- Donaghue, K. C., Chiarelli, F., Trotta, D., Allgrove, J., & Dahl-Jorgensen, K.
- Venue
- Pediatric Diabetes
- Publisher
- Wiley
- Published
- 2009-09
- Volume
- 10
- Pages
- 195-203
- ISSN
- 1399-543X (ISSN-L)
- 1399-5448
- OpenAlex
- W2001877414
- Cited by
- 188
- References
- 9
- FWCI
- 12.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microvascular and macrovascular complications associated with diabetes in children and adolescents. https://app.cochat.ai/papers/10.1111/j.1399-5448.2009.00576.x
- The paper
- Donaghue, K. C., Chiarelli, F., Trotta, D., Allgrove, J., & Dahl-Jorgensen, K. (2009). Microvascular and macrovascular complications associated with diabetes in children and adolescents. Pediatric Diabetes. https://doi.org/10.1111/j.1399-5448.2009.00576.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.